HK1257129A1 - 含有吲哚衍生物的药物组合物、其制备方法和用途 - Google Patents
含有吲哚衍生物的药物组合物、其制备方法和用途 Download PDFInfo
- Publication number
- HK1257129A1 HK1257129A1 HK18116383.1A HK18116383A HK1257129A1 HK 1257129 A1 HK1257129 A1 HK 1257129A1 HK 18116383 A HK18116383 A HK 18116383A HK 1257129 A1 HK1257129 A1 HK 1257129A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compound
- pharmaceutical composition
- cancer
- dihydrochloride
- precipitate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1500520 | 2015-12-18 | ||
| SE1500520-0 | 2015-12-18 | ||
| PCT/EP2016/025175 WO2017102097A1 (en) | 2015-12-18 | 2016-12-10 | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1257129A1 true HK1257129A1 (zh) | 2019-10-11 |
Family
ID=58231562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18116383.1A HK1257129A1 (zh) | 2015-12-18 | 2016-12-10 | 含有吲哚衍生物的药物组合物、其制备方法和用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10668056B2 (enExample) |
| EP (1) | EP3390403B1 (enExample) |
| JP (2) | JP6929299B2 (enExample) |
| CN (1) | CN108431003A (enExample) |
| AU (1) | AU2016371541B2 (enExample) |
| CA (1) | CA3008084A1 (enExample) |
| DK (1) | DK3390403T3 (enExample) |
| EA (1) | EA039778B1 (enExample) |
| ES (1) | ES2925690T3 (enExample) |
| HK (1) | HK1257129A1 (enExample) |
| HU (1) | HUE059610T2 (enExample) |
| PL (1) | PL3390403T3 (enExample) |
| PT (1) | PT3390403T (enExample) |
| WO (1) | WO2017102097A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017102097A1 (en) * | 2015-12-18 | 2017-06-22 | Vivolux Ab | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof |
| WO2021044608A1 (ja) * | 2019-09-06 | 2021-03-11 | シミックホールディングス株式会社 | ダントロレン水性製剤及びその調製方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660737B2 (en) * | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
| US20060217437A1 (en) * | 2005-03-17 | 2006-09-28 | Burmester James K | TGF-beta modulators and methods for using the same |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| CN103547268B (zh) * | 2011-03-21 | 2017-02-22 | 威沃路克斯股份公司 | 实体瘤的治疗 |
| DK2900667T3 (da) * | 2012-09-21 | 2019-08-26 | Vivolux Ab | Middel og fremgangsmåde til behandling af faste tumorer |
| WO2017102097A1 (en) * | 2015-12-18 | 2017-06-22 | Vivolux Ab | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof |
-
2016
- 2016-12-10 WO PCT/EP2016/025175 patent/WO2017102097A1/en not_active Ceased
- 2016-12-10 ES ES16843253T patent/ES2925690T3/es active Active
- 2016-12-10 HK HK18116383.1A patent/HK1257129A1/zh unknown
- 2016-12-10 CA CA3008084A patent/CA3008084A1/en active Pending
- 2016-12-10 US US16/061,868 patent/US10668056B2/en active Active
- 2016-12-10 PL PL16843253.2T patent/PL3390403T3/pl unknown
- 2016-12-10 EA EA201891027A patent/EA039778B1/ru unknown
- 2016-12-10 DK DK16843253.2T patent/DK3390403T3/da active
- 2016-12-10 EP EP16843253.2A patent/EP3390403B1/en active Active
- 2016-12-10 PT PT168432532T patent/PT3390403T/pt unknown
- 2016-12-10 HU HUE16843253A patent/HUE059610T2/hu unknown
- 2016-12-10 JP JP2018550649A patent/JP6929299B2/ja not_active Expired - Fee Related
- 2016-12-10 CN CN201680074239.0A patent/CN108431003A/zh active Pending
- 2016-12-10 AU AU2016371541A patent/AU2016371541B2/en not_active Ceased
-
2021
- 2021-05-07 JP JP2021079373A patent/JP2021130673A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3390403T3 (pl) | 2022-10-24 |
| EP3390403B1 (en) | 2022-06-29 |
| US20180280366A1 (en) | 2018-10-04 |
| JP2019505571A (ja) | 2019-02-28 |
| CN108431003A (zh) | 2018-08-21 |
| EA201891027A1 (ru) | 2019-02-28 |
| CA3008084A1 (en) | 2017-06-22 |
| US10668056B2 (en) | 2020-06-02 |
| JP2021130673A (ja) | 2021-09-09 |
| HUE059610T2 (hu) | 2022-12-28 |
| EP3390403A1 (en) | 2018-10-24 |
| WO2017102097A1 (en) | 2017-06-22 |
| EA039778B1 (ru) | 2022-03-14 |
| AU2016371541A1 (en) | 2018-06-07 |
| DK3390403T3 (da) | 2022-08-29 |
| AU2016371541B2 (en) | 2021-07-08 |
| ES2925690T3 (es) | 2022-10-19 |
| PT3390403T (pt) | 2022-09-06 |
| JP6929299B2 (ja) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109563100B (zh) | 三唑并嘧啶化合物的晶体形式 | |
| TWI259081B (en) | Treatment of acute myeloid leukemia with indolinone compounds | |
| JP7260606B2 (ja) | 固体形態のｃｄｋ４阻害薬 | |
| KR102342776B1 (ko) | (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법 | |
| US20150105377A1 (en) | Methods and Compositions for RAF Kinase Mediated Diseases | |
| CN101365708B (zh) | 1-苯甲酰基-4-[2-[4-甲氧基-7-(3-甲基-1h-1,2,4-三唑-1-基)-1-[(膦酰氧基)甲基]-1h-吡唑并[2,3-c]吡啶-3-基]-1,2-二氧代乙基]-哌嗪的结晶形式 | |
| CN119350242B (zh) | 靶向krasg12d的取代喹啉酮类化合物及其应用 | |
| TWI415613B (zh) | Anti-cancer agent resistance to overcome the agent | |
| CN112010839B (zh) | 靶向丝/苏氨酸激酶抑制剂的晶型 | |
| JP2019529475A (ja) | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 | |
| AU2018327414A1 (en) | Substituted imidazoquinolines | |
| JP2021130673A (ja) | インドール誘導体を含む医薬組成物、その調製方法及びその使用 | |
| AU2018329152A1 (en) | Substituted imidazoquinolines as agonists of TLR7 | |
| US20220096412A1 (en) | Combination Drug Substance of Polyamine Transport Inhibitor and DFMO | |
| JP6073480B2 (ja) | ＰＩ３Ｋおよび／またはｍＴＯＲ阻害剤 | |
| KR20180011949A (ko) | 신규한 2-아민 치환 1,4-나프토퀴논 화합물 및 이를 포함하는 암의 예방 또는 치료용 약제학적 조성물 | |
| EP4631937A1 (en) | Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof | |
| KR101995533B1 (ko) | [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| WO2024040241A1 (en) | Pharmaceutical formulations, processes for preparation, and methods of use | |
| JP2025527820A (ja) | キノリン誘導体阻害剤の結晶形、及びその調製方法並びに用途 | |
| RU2419431C1 (ru) | ПРОИЗВОДНЫЕ β-КАРБОЛИНА, ОБЛАДАЮЩИЕ ПРОТИВОТУБЕРКУЛЕЗНОЙ АКТИВНОСТЬЮ, ИХ ПРИМЕНЕНИЯ ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА, СПОСОБ ИХ СИНТЕЗА, А ТАКЖЕ НОВЫЕ МЕТОДЫ ЛЕЧЕНИЯ С ИХ ИСПОЛЬЗОВАНИЕМ | |
| BR112018076443B1 (pt) | Processo de preparação de formas cristalinas de um composto de triazolopirimidina | |
| BR122024009277A2 (pt) | Formas cristalinas de um composto de triazolopirimidina | |
| HK1210464B (en) | Pi3k and/or mtor inhibitor |